Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2024 08:30 ET | Source: CytoDyn Inc.

CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology

VANCOUVER, Washington, Nov. 25, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
November 04, 2024 08:30 ET | Source: CytoDyn Inc.

CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial

VANCOUVER, Washington, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
October 30, 2024 08:30 ET | Source: CytoDyn Inc.

CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories

VANCOUVER, Wash., Oct. 30, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for...
October 08, 2024 08:30 ET | Source: CytoDyn Inc.

CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development

VANCOUVER, Washington, Oct. 08, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
October 07, 2024 11:05 ET | Source: CytoDyn Inc.

CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques

Abstract to be presented at the 5th annual HIV Research for Prevention Conference Study results highlight potential for treatment VANCOUVER, Washington, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoDyn...
October 04, 2024 08:30 ET | Source: CytoDyn Inc.

CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial

VANCOUVER, Washington, Oct. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
September 24, 2024 08:30 ET | Source: CytoDyn Inc.

CytoDyn Announces Preliminary Findings in Study with SMC Laboratories

VANCOUVER, Washington, Sept. 24, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
September 09, 2024 08:30 ET | Source: CytoDyn Inc.

September 2024 Letter to Shareholders

VANCOUVER, Washington, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, It continues to be a transformative year for CytoDyn Inc. (“CytoDyn” or the “Company”). A year in which we have made...
August 23, 2024 08:30 ET | Source: CytoDyn Inc.

CytoDyn Engages Leading CRO For Phase II Inflammation Trial

VANCOUVER, Washington, Aug. 23, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
August 12, 2024 08:30 ET | Source: CytoDyn Inc.

CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer

VANCOUVER, Washington, Aug. 12, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...